INTRODUCTION
============

The packaging of eukaryotic DNA into nucleosomes and higher order structures represents an obstacle for transcription initiation and elongation ([@B1],[@B2]). Different nuclear machineries are responsible for the reorganization of interactions within the chromatin which allows specific and general transcription factors to gain access to their targets in the DNA and to carry out gene transcription in a tightly regulated manner. A specific type of chromatin remodeling machine uses the energy of ATP hydrolysis to alter interactions between histones and DNA within the nucleosome ([@B3]). It is believed that ATP-dependent chromatin remodeling machines (CRMs) are able to move nucleosomes, reorganize their structure and composition or even remove them ([@B4]). All ATP-dependent CRMs contain a DNA-dependent ATPase of the SNF2 family, which is considered as the catalytic subunit responsible for the remodeling. According to the sequence homology of their conserved ATPase domains, SNF2 proteins have been classified into distinct subfamilies such as SWI2/SNF2, ISWI, CHD1, Mi-2, CHD7, INO80, etc. ([@B5]).

Many authors have shown how ATP-dependent CRMs positively or negatively affect the formation of the transcription pre-initiation complex ([@B6; @B7; @B8; @B9; @B10; @B11; @B12]) but, on the contrary, little is known about how these enzymes may affect subsequent steps of the transcription cycle such as elongation or termination. The RNA polymerase II (RNAPII) complex is very inefficient at transcribing chromatinized templates *in vitro* ([@B1]). In fact, biochemical studies have revealed that nucleosomes represent a strong barrier against elongation, so that RNAPII stops at certain arrest sites near them, becoming blocked in a catalytically inactive state ([@B13],[@B14]). Two elongation complexes, FACT (facilitates chromatin transcription) ([@B15]) and CTEA (chromatin transcription enabling activity) ([@B16]), have been shown to stimulate RNAPII passage through a nucleosome. However, whether ATP-dependent chromatin remodeling enzymes are also required to remodel nucleosomes during RNAPII elongation is still unclear. In this respect, Kingston and colleagues reported that the SWI/SNF complex, one of the best characterized ATP-dependent CRMs, which contains an ATPase of the SWI2/SNF2 subfamily, enhances HSF1-mediated stimulation of promoter-proximal paused RNAPII *in vitro* ([@B17]). Furthermore, Carey *et al*. also demonstrated a role for SWI/SNF and the related RSC complex in elongation *in vitro*, as they are able to release RNAPII from the blockade caused by a positioned nucleosome ([@B18]). Despite these facts, so far there is no clear evidence *in vivo* for a role of SWI/SNF-type CRMs in elongation.

On the other hand, CHD1 (chromodomain-ATPase/helicase-DNA-binding domain 1), another SNF2-like ATPase belonging to the so called CHD1 subfamily, does appear to function in both elongation and termination. In yeast and flies CHD1 associates with highly active transcription sites ([@B19],[@B20]). Furthermore, CHD1 mutant alleles in yeast are sensitive to 6-azauracil ([@B21]) and genetically interact with Set2 and Spt5, both involved in elongation ([@B20],[@B22]). Finally, CHD1 physically associates with factors involved in elongation such as the polymerase II-associated complex (PAF), DSIF (DRB-sensitivity-inducing factor) and FACT ([@B20],[@B23],[@B24]). These results strongly indicate that CHD1 works as an elongation factor *in vivo*, although very little mechanistic data had been provided until recently, when Konev *et al*. ([@B25]) showed that *Drosophila* CHD1 is involved in histone H3.3 replacement in the transcriptionally silent male pronucleus. Moreover, the *Schizosaccharomyces pombe* homolog of CHD1, Hrp1, has been shown to function in loading of the centromere-specific H3 variant CENP-A ([@B26]). Therefore, CHD1 also may have a general role in replication-independent nucleosome assembly. The connection between this CHD1 function and its role in elongation remains unknown.

In addition to CHD1, there are other eight CHD proteins in mammalian cells, which are classified into three subfamilies called CHD1 (CHD1 and CHD2), Mi-2 (CHD3 to CHD5) and CHD7 (CHD6 to CHD9) subfamilies ([@B5],[@B27]). Here we have investigated the role of CHD8 in transcription. In addition to the typical helicase-like domain that characterizes the SNF2 family, CHD8 contains two tandem chromodomains within the amino-terminal half of the protein. Chromodomains are evolutionary conserved motifs involved in interactions with DNA, RNA or methylated lysines ([@B28]). Moreover, CHD8 also contains a SANT domain and two BRK domains with unclear functions. CHD8 has been shown to interact with CTCF and is required for CTCF-dependent insulator activity ([@B29]). Recently, it has also been shown that CHD8 interacts with the human proteins Staf and β-catenin and contributes to regulate *U6* and β-catenin-dependent gene transcription ([@B30],[@B31]). We found that CHD8 is required for cell proliferation. CHD8 positively controls the expression of cyclin E2 (*CCNE2)* and thymidylate synthetase (*TYMS)*, two genes specifically expressed in the G1/S transition. Furthermore, CHD8 associates constitutively with the promoter and the transcribed 5′ region of its target genes and interacts with elongating RNAPII, suggesting a role for this protein in transcription elongation.

MATERIALS AND METHODS
=====================

Cell culture, growth curves and cell-cycle analyses
---------------------------------------------------

All cells were maintained in Dulbecco\'s modified Eagle\'s medium (DMEM) supplemented with 7% fetal bovine serum, 100 units/ml penicillin and 100 µg/ml streptomycin, and were cultivated in a 37°C incubator with 5% CO~2~. For cell growth analysis, 2 × 10^5^ C33KD1, C33KD2 and HeLaKD1 cells were seeded in 10 cm plates, with or without 2 µg/ml doxycycline (Sigma). At the indicated times cells were collected and counted using a Neubauer haemocytometer. Cell-cycle analysis was carried out using BD FACSCalibur flow cytometer (BD Biosciences), as previously described ([@B32]). When required cultures were treated with Flavopiridol (Sanofi-Aventis) or DRB (Sigma) at the indicated final concentration. Stock solution of Flavopiridol 10 mM was prepared in DMSO. For BrdU cell proliferation assays, cells were labeled with 10 mM BrdU during 15 min. BrdU incorporation was detected using the 5-bromo-2′-deoxy-uridine Labeling and Detection Kit I (Roche).

Cells were synchronized by double thymidine blocking as previously described ([@B33]), except that samples were taken at the following times after blocking release: *t* = 0 h (G1/S phase), *t* = 4 h (S phase), *t* = 14 h (early G1 phase) and *t* = 18 h (late G1 phase). The cell-cycle stage of each population was determined by flow cytometry analysis.

Plasmid constructs
------------------

To make pTER-CHD8-1 and pTER-CHD8-2, annealed gene-specific oligonucleotides encoding shRNA1 or shRNA2 ([Supplementary Table S2](http://nar.oxfordjournals.org/cgi/content/full/gkp101/DC1)) were ligated into pTER ([@B34]) and pSUPER vectors ([@B35]) previously digested with *Bgl*II and *Hind*III.

The pRSV-CHD8 expression vector containing the CHD8 protein (2581 amino acids) was constructed as follows: first, a *Blp*I-*Not*I fragment from pBC SK (+)-KIAA1564 (provided by the Kazusa DNA Research Institute, Japan) was cloned into a pTriplEx2 (BD Biosciences) containing the EST AV762074 (provided by the Chinese National Human Genome Center, China) to constitute pTriplEx2-*CHD8*. After that, a *Pml*I restriction site was inserted before the *CHD8* sequence using standard PCR techniques and, finally, a *Pml*I-*Not*I fragment from the former construct was cloned into a pAdRSV-Sp ([@B36]) derivative containing an in-frame FLAG epitope, and previously linearized with *Pml*I and *Not*I.

For Luciferase reporter assays, pCycE2 was constructed by inserting a PCR fragment ranging from nucleotide −960 to nucleotide +60 of *CCNE2* gene into pCycE ([@B37]) previously digested with *Hind*III and *Not*I.

To make pGEX-CD1, pGEX-CD2, pGEX-CD1+CD2, and pGEX-CD1+mutCD2, pGEX-mutCD1+CD2 fragments encoding CHD8 CD1 (residues 629--715), CD2 (residues 710--785), CD1+CD2 (residues 629--785), CD1+mutCD2 (residues 629--785, W751L, Y756L), and mutCD1+CD2 (residues 629--785, Y672L, Y675L, Y677L), were cloned into a pGEX-4T-2 vector (GE Healthcare) using standard PCR techniques. All constructs were verified by DNA sequencing.

Generation of inducible knockdown cell lines
--------------------------------------------

To generate inducible shRNA CHD8 knockdown cell lines, C33A and HeLa cells were co-transfected with pCDNA~6~TR (Invitrogen) and pTER-CHD8-1. Resistant clones were selected in the presence of 100 µg/ml Zeocin and 5 µg/ml Blasticidin, and tested for their ability to down-regulate CHD8 by immunoblotting, at different times after the addition of 2 µg/ml Dox.

ChIP assays
-----------

ChIP assays were basically performed as described by Upstate/Millipore (<http://www.millipore.com/techpublications/tech1/mcproto407>). ChIP data are the average of 12--18 real-time PCR quantifications from two to three independent experiments. Real-time PCRs were performed in an Applied Biosystems 7500 FAST Real-Time PCR System, using the Applied Biosystems Power SYBR Green Master Mix and protocols. ChIP was quantified relative to inputs using the method described in ([@B38]). Specific primers for *CCNE2*, *TYMS* and β-*Actin (ACTB)* were designed using the Primer Express 3.0 software (Applied Biosystems) and are described in the [Supplementary Table S2](http://nar.oxfordjournals.org/cgi/content/full/gkp101/DC1).

Antibodies used in ChIP assays include polyclonal α-CHD8 (30 µl per sample), α-H3K4me3, α-H3K4me2 (Upstate/Millipore) (5 µl per sample) and α-RNAPII N-20 (Santa Cruz Biotechnologies) (5 µl per sample).

Antibodies, immunoblotting and immunoprecipitations
---------------------------------------------------

Immunobloting experiments were carried out as previously described ([@B39]). Co-immunoprecipitations were carried out as described ([@B40]). To detect CHD8, a rabbit polyclonal serum raised against a GST fusion protein containing human CHD8 residues 16--227 was used. Commercial antibodies used for immunoblotting include α-CCNE2 (Cell Signalling Technology), α-E2F1 (KH95), α-SPT5 (H-300), α-BRAF35 (4.21), α-RNAPII (N-20) (Santa Cruz Biotechnology), α-Ser5-P-RNAPII (CTD4H8, Upstate-Millipore), α-RNAPIIa (8WG16), α-Ser2-P-RNAPII (H5) and α-Ser5-P-RNAPII (H14) (Covance).

Gene-expression analysis
------------------------

RNA was isolated using the RNeasy Mini kit (Qiagen). cDNA was synthesized from 3 µg of total RNA with the SuperScript First-Strand Synthesis system for RT--PCR (Invitrogen). One-twentieth of the reaction was used for PCR amplification with specific primers spanning an intron as a control for DNA contamination. To keep the amplification within the quantitative range, the number of cycles, usually 12--25, was set up for each experiment. Products were detected by Southern blot, using an InstantImager Electronic Autoradiography device (Packard Instrument) for quantification of radioactive areas. Gene-specific primers used in RT--PCR experiments are described in the [Supplementary Table S2](http://nar.oxfordjournals.org/cgi/content/full/gkp101/DC1).

Microarray gene-expression analysis
-----------------------------------

Total RNA samples coming from C33KD2 cells cultured for 48 h either with or without 2 µg/ml doxycycline were used to generate complementary RNA labeled either with Cyanine 3 or Cyanine 5 with the Agilent Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). Dye incorporation was determined with a NanoDrop spectrophotometer. Once labeling was completed, both samples were combined and hybridized to a whole human genome Agilent 44K 60-mer Oligo Microarray (Agilent Technologies) according to manufacturer\'s instructions. The experiment was performed in triplicate in order to achieve statistical significance. The microarrays were scanned on an Agilent G2565 scanner (Agilent Technologies) and images were extracted and quality assessed with the Agilent Feature Extraction software (Agilent Technologies). Data from the three individual hybridizations were normalized using the RMA algorithm, and the data were then further analyzed using the microarray software package Genespring GX 7.3 software (Agilent Technologies). Microarray data have been deposited in the GEO (Gene Expression Omnibus) database with the accession number GSE11422.

Luciferase reporter assays
--------------------------

For luciferase reporter assays, 2 × 10^5^ COS-7 cells per well were seeded in six-well plates and co-transfected with 200 ng of the luciferase reporter vectors, pCycE2, or pMMTV-Luc, and increasing quantities of pRSV-CHD8, by using Fugene-6 (Roche). Luciferase activity was determined 36 h after transfection with Lysis Solution 1× (Promega), Luciferase Substrate (Promega) and a GloMax 20/20 luminometer (Promega), following the manufacturer\'s instructions. All transfections were normalized by measuring β-galactosidase activity of the samples. Data are the average of at least three independent experiments and error bars indicate standard deviation.

Peptide binding assays
----------------------

Sequences encoding CHD8 CD1 (residues 629--715), CD2 (residues 710--785) CD1+CD2 (residues 629--785), CD1+mutCD2 (residues 629--785, W751L, Y756L) and mutCD1+CD2 (residues 629--785, Y672L, Y675L, Y677L) were expressed as GST fusion proteins in BL21 (DE3) bacterial cells and purified using standard procedures. For binding assays, 0.5 µg of each GST fusion protein were incubated with 2 µg biotinylated di-methylated Lys 4, tri-methylated Lys 4, di-methylated Lys 9 or unmodified histone H3 peptides (Upstate), in a 200 µl reaction using 156 µl of interaction buffer (20 mM HEPES pH 7.5, 500 mM NaCl, 1 mM EDTA, 0.2% (v/v) NP-40, 0.25% BSA and protease inhibitors), for 2 h at 4°C with rotation. Then, 15 µl Dynabeads M-280 Streptavidin (Dynal Biotech) were added to the samples for an additional hour and, after three washes in interaction buffer, each one was eluted with 20 µl Laemmli buffer 2× and subjected to western blot analysis using an α-GST antibody.

RESULTS
=======

Depletion of CHD8 impairs cell proliferation
--------------------------------------------

In order to identify CHD8 functions we decided to decrease the expression of *CHD8* by a doxycycline-regulated inducible shRNA expression vector ([@B34]). For that, two knockdown stable cell lines (C33KD1 and C33KD2) were derived from human C33A cervical carcinoma cells. Both lines showed a significant reduction in the level of CHD8 expression upon doxycycline (Dox) addition (85% reduction after 72 h), as determined by immunoblotting ([Figure 1](#F1){ref-type="fig"}A). RT--PCR experiments demonstrated that expression of the closely related paralogous genes *CHD6*, *CHD7* and *CHD9* was unaffected, indicating that the knockdown was specific ([Supplementary Figure S1](http://nar.oxfordjournals.org/cgi/content/full/gkp101/DC1)). To determine whether reduced CHD8 levels affect cell proliferation, the growth rate of C33KD1 and C33KD2 cell lines was studied in the presence or the absence of Dox. Both cell lines exhibited a slower growth rate under conditions of CHD8 depletion, indicating that CHD8 is required for C33A cell proliferation ([Figure 1](#F1){ref-type="fig"}B). As a control, we verified that Dox had no effect on the growth rate of C33A cells (data not shown). To extend our results to another cell line we generated knockdown HeLa clones that showed identical defects in proliferation under conditions of CHD8 depletion ([Supplementary Figures S2A and B](http://nar.oxfordjournals.org/cgi/content/full/gkp101/DC1)). FACS analysis of proliferating C33KD1 and C33KD2 cells demonstrated that knockdown of CHD8 reduced the S-phase cell population from ∼40% to 32%, with a concomitant increase in the G1 cell population from about 40--50%. Meanwhile, the G2/M cell population remained essentially unchanged ([Figure 1](#F1){ref-type="fig"}C). Consistently, BrdU incorporation experiments revealed that upon a 15-min pulse of BrdU around 50% of the cells were able to incorporate BrdU in the absence of Dox but only about 35% of the CHD8-depleted cells were BrdU-positive ([Figure 1](#F1){ref-type="fig"}D). These data suggest that CHD8 positively regulates the cell cycle by facilitating the G1/S transition. Figure 1.Depletion of CHD8 impairs cell proliferation. CHD8 shRNA knockdown cell lines (C33KD1 and C33KD2) were generated by stable transfection of C33A cells. (**A**) Immunoblot analysis of Dox-treated (+) and non-treated (−) cells after 72 h, using α-CHD8 antibody. α-Ser2-P RNAPII antibody (H5) was used as a loading control. (**B**) Growth curve of CHD8 knockdown cell lines in the presence or absence of Dox. Data are the average of three independent experiments. Error bars represent standard deviation. (**C**) Flow cytometry analysis of asynchronous C33KD1 and C33KD2 cells treated with or without Dox for 72 h. Representative experiments are shown. Numbers are the average of three independent experiments. (**D**) BrdU incorporation analysis of cycling cells. C33KD1 and C33KD2 cells treated or non-treated with Dox for 48 and 72 h were labeled with BrdU as described in Methods. Percentage of cells that had incorporated BrdU was determined by immunofluorescence using α-BrdU antibodies. Numbers are the average of two independent experiments.

CHD8 contributes to the expression of *CCNE2* and *TYMS* genes
--------------------------------------------------------------

To identify CHD8 target genes we compared the genome-wide expression profiling of C33KD2 cells after Dox addition with that of non-treated cells. For this purpose, cells were collected after only 48 h of Dox treatment, when CHD8 levels were about 40% of its original quantity (data not shown). This was thought to avoid secondary effects produced by a pronounced growth arrest and to increase the probability of identifying direct target genes. Three independent biological replicates were performed. Taking into consideration only transcripts with a log~2~(+Dox/--Dox expression ratio) \>0.5 or \<−0.5, with statistically significant *P* values ≤0.01, 10 and 31 genes were found to be up-regulated and down-regulated, respectively, in CHD8-depleted cells compared to non-depleted cells ([Supplementary Table S1](http://nar.oxfordjournals.org/cgi/content/full/gkp101/DC1)). As expected, levels of the *CHD8* transcript were down-regulated in the CHD8-depleted cells. Efficiency of the microarray-based identification of CHD8-dependent genes was confirmed by RT--PCR analyses of a subset of misregulated genes ([Supplementary Figure S3](http://nar.oxfordjournals.org/cgi/content/full/gkp101/DC1)). Given the cell-cycle progression defects observed in the CHD8-depleted cells, we specifically focused on the cell-cycle-related genes among the CHD8-dependent ones. Interestingly, cyclin E2 (*CCNE2*) and thymidylate synthetase (*TYMS*), two E2F1-dependent genes expressed during the G1/S transition ([@B41]), were found to be down-regulated in CHD8-depleted cells ([Figure 2](#F2){ref-type="fig"}A, B and C and [Table 1](#T1){ref-type="table"}). As a control, we verified that the expression of these two genes was not affected by Dox in C33A cells (data not shown). These results led us to explore the possibility that other genes specifically expressed in the G1/S cell-cycle transition were also misregulated in CHD8-depleted cells. Expression of none of the tested genes (*CCNE1*, cyclin E1; *CCNA2*, cyclin A; *TK1*, thymidine kinase; *E2F1* or *PCNA*) was found to be significantly altered upon Dox addition ([Figure 2](#F2){ref-type="fig"}A, B and C) indicating that the reduction in the amount of *CCNE2* and *TYMS* transcripts is not a consequence of the G1 arrest provoked by the depletion of CHD8. Down-regulation of cyclin E2 was also verified using two independent shRNAs targeting two different regions of the *CHD8* mRNA ([Supplementary Figure S4](http://nar.oxfordjournals.org/cgi/content/full/gkp101/DC1)), as well as in CHD8-depleted HeLa cells ([Supplementary Figure S2C](http://nar.oxfordjournals.org/cgi/content/full/gkp101/DC1)). Figure 2.Depletion of CHD8 leads to down-regulation of *TYMS* and *CCNE2* genes. (**A**) Transcript levels of genes induced at the G1/S transition (*TYMS, CCNE2, CCNE1, CCNA2, TK1*) were analyzed by RT--PCR in Dox-treated (+) or non-treated (−) C33KD2 cells, at the indicated times. β-Actin (*ACTB)* transcript levels were also determined as a control for the amount of input cDNA. (**B**) Quantification of signals shown in (A). Values were normalized to the *ACTB* gene transcript level. The level of cDNA amplified in Dox non-treated cells (−) was considered 100%. Values are the average of three independent experiments. Bars indicate standard error of the mean. (**C**) Levels of CHD8, CCNE2, E2F1 and PCNA proteins were analyzed by immunoblot in C33KD2 cells treated (+) or non-treated (−) with Dox during the indicated time. α-Ser2-P-RNAPII antibody (H5) was used as a loading control. (**D**) The *CCNE2* promoter is activated by CHD8. COS-7 cells were transfected with 0.2 µg of pCycE2-LUC plasmid along with 0.3 or 0.7 µg of pRSV-CHD8 plasmid. 0.2 µg of the pMMTV-LUC plasmid were co-transfected with a glucocorticoid receptor expression vector (0.2 µg) and with or without 0.7 µg of pRSV-CHD8. When indicated, the glucocorticoid receptor ligand dexamethasone (DEX) was added at 1 µg/ml for 12 h. Values are the average of three independent experiments ± SD. Table 1.Selection of up- and down-regulated transcripts in *CHD8*-depleted cellsGene symbolGene product descriptionFold changeUp-regulated genes*CSH1*Chorionic somatomammotropin hormone 12.7321*NUPL1*Nucleoporin like 11.8661*DKFZp451J1719*YOD1 deubiquinating enzyme 1 homolog1.8150*ARHGEF12*Rho guanine nucleotide exchange factor (GEF) 121.6586*CRADD*CASP2 and RIPK1 domain containing adaptor with death domain1.5052*RASA2*RAS p21 protein activator 21.4044Down-regulated genes*CDK2AP1*CDK2-associated protein 10.71203*DHX29*DEAH (Asp-Glu-Ala-His) box polypeptide 290.70222*USP11*Ubiquitin specific protease 110.69737*KLF13*Kruppel-like factor 130.69737*NUCKS*Nuclear ubiquitous casein kinase and cyclin-dependent kinase substrate0.69255*ROR1*Receptor tyrosine kinase-like orphan receptor 10.67830*CCNE2*Cyclin E20.67362*KLF15*Kruppel-like factor 150.66896*PORIMIN*Pro-oncosis receptor inducing membrane injury gene0.66896*ZNF655*Zinc finger protein 6550.66896*AGPAT3*1-Acylglycerol-3-phosphate O-acyltransferase 30.64171*CHD8*Chromodomain helicase DNA binding protein 80.63728*NIN*Ninein (GSK3B interacting protein)0.62417*TYMS*Thymidylate synthetase0.61132*CRISP3*Cysteine-rich secretory protein 30.52851*KIN*KIN antigenic determinant of recA protein homolog0.35111

To verify whether *CCNE2* is a direct target of CHD8, a promoter-reporter construct was co-transfected with increasing quantities of a CHD8 expression vector and the expression of the *luc* reporter gene was determined. As shown in [Figure 2](#F2){ref-type="fig"}D, CHD8 stimulated about 4-fold the activity of the promoter. As a negative control, CHD8 was not able to activate the MMTV promoter either in the absence or in the presence of dexamethasone, its inductor. To further investigate whether *CCNE2* and *TYMS* are direct targets of CHD8 *in vivo*, we performed chromatin immunoprecipitation (ChIP) assays in C33A cells. [Figure 3](#F3){ref-type="fig"}A shows that CHD8 binds to the 5′ region of these genes. Depletion of CHD8 upon Dox addition to C33KD2 cells led to a significant reduction in the amount of immunoprecipitated *CCNE2* and *TYMS* chromatin, which confirms the specificity of the α-CHD8 antibodies in our ChIP assays ([Figure 3](#F3){ref-type="fig"}B and C). Next, we decided to investigate the precise location of CHD8 within the *CCNE2* gene. As shown in [Figure 3](#F3){ref-type="fig"}D, CHD8 was enriched in the promoter and the transcribed 5′ region of the gene. Figure 3.Analysis of the presence of CHD8 in the 5′ region of the *CCNE2* and *TYMS* genes by ChIP. (**A**) Crosslinked DNA--protein complexes from C33A cells were immunoprecipitated with α-CHD8 and α-H3K4me3 (as a positive control). PCR amplification was performed with specific primers of the *CCNE2*, *TYMS* and *ACTB* genes. The center of PCR products relative to the transcription start sites is as follows: +836 for the *CCNE2*, +91 for the *TYMS* and +1294 for the *ACTB* genes. (**B** and **C**) Binding of CHD8 to the *CCNE2* (B) and *TYMS* (C) genes in C33KD2 cells treated or not with Dox for 72 h. (**D**) Distribution of CHD8 over the *CCNE2* gene in C33A cells. Numbers correspond to the center nucleotide of the real time PCR product relative to the transcription start site. A diagram of the *CCNE2* gene is also shown. Black boxes correspond to coding exons while grey boxes correspond to the 5′UTR and 3′UTR. Transcription start point (+1) and ATG are also indicated. In (B), (C) and (D), immunoprecipitated DNA from three independent experiments was quantified using qPCR and expressed as percentage of the input (B and C) or as fold enrichment respect to the −11 058 amplicon (D). PI, pre-immune serum.

*CCNE2* is an E2F-dependent gene transcriptionally active only during the G1/S and S phase fractions of the cell cycle ([@B41],[@B42]) ([Figure 4](#F4){ref-type="fig"}B and C). Thus, we wondered whether the association of CHD8 with the *CCNE2* gene was cell-cycle-regulated. For that, we synchronized HeLa cells in G1/S by double thymidine blocking and performed ChIP experiments at different cell-cycle stages obtained by differential timed release in normal media. Given our interest in the G1/S transition, we used cell populations synchronized at early G1, late G1, G1/S and S ([Figure 4](#F4){ref-type="fig"}A). As shown in [Figure 4](#F4){ref-type="fig"}B and C, while the levels of CHD8 were not affected by the cell cycle, *CCNE2* was only expressed at the G1/S and S fractions. ChIP experiments evidenced that CHD8 remains bound to the *CCNE2* gene during the entire cell cycle ([Figure 4](#F4){ref-type="fig"}D). Interestingly, a constitutive RNAPII occupancy at the *CCNE2* promoter-proximal region was also observed ([Figure 4](#F4){ref-type="fig"}E), suggesting that RNAPII is paused at the *CCNE2* gene during both early and late G1 fractions, when the gene is not transcriptionally active ([Figure 4](#F4){ref-type="fig"}B and C). However, a significant increase of RNAPII occupancy in the promoter and in body of the gene was observed at the G1/S transition coincident with the activation of the gene ([Figure 4](#F4){ref-type="fig"}E). Figure 4.CHD8 and RNAPII bind to *CCNE2* promoter-proximal region regardless of the cell-cycle phase. (**A**) HeLa cells were synchronized by double thymidine blocking as described in 'Materials and Methods' section. After the release of the blockade (*t* = 0), samples were taken at the indicated times for flow cytometry analysis. Synchronized cells were taken at the indicated times and levels of *CCNE2* and *ACTB* transcripts (**B**) and CHD8, Cyclin E2 and E2F1 proteins (**C**) were determined by RT--PCR and immunoblot analysis, respectively. α-E2F1 was used as a control of a typical G1/S- and S-expressed gene. α-Ser2-P-RNAPII antibody (H5) was used as a loading control for immunoblotting experiments. (**D** and **E**) ChIP analysis of the binding of CHD8 (D) and total RNAPII (N20 antibody) (E) to the *CCNE2* gene in different cell-cycle phases. Numbers correspond to the center nucleotide of the real-time PCR product relative to the transcription start site. Data are the average of 12 qPCR determinations from two independent experiments.

The tandem chromodomains of CHD8 bind H3K4me2 *in vitro*
--------------------------------------------------------

CHD8 contains two chromodomains (CDs) within its amino-terminal half. Chromodomains have been shown to mediate interactions of chromatin factors with methylated lysines of the histone tails. In fact, the similar CHD1 tandem chromodomains bind histone H3 tri-methylated in lysine 4 ([@B43],[@B44]). Therefore, we decided to investigate whether the tandem CDs of CHD8 directly bind methylated H3K4, *in vitro*. For that, its first (CD1), second (CD2) or tandem chromodomains (CD1+CD2) ([Figure 5](#F5){ref-type="fig"}A) were expressed in *Escherichia coli* as GST-fusion proteins. Recombinant purified proteins were incubated with biotinylated peptides corresponding to the first 21 amino acids of histone H3, either unmodified or modified by methylation in lysine 4 (di-methylated or tri-methylated) or in lysine 9 (di-methylated). [Figure 5](#F5){ref-type="fig"}B shows that while CD1 was unable to interact with any histone H3 peptide, CD2 bound the four peptides without significant preference. More importantly, the tandem chromodomains mostly interacted with the H3K4me2 peptide. Single chromodomain proteins bind to methylated lysines by interaction with several aromatic residues (aromatic cage) ([@B28]). Thus, mutation of the conserved aromatic residues W751 and Y756 of CD2 completely abolished the binding activity of the tandem chromodomains. However, a triple mutation of the conserved aromatic residues (Y672L, Y675L, Y677L) of CD1 does not affect the binding. Therefore, our data suggest that CD1 contribution to the binding specificity does not require its aromatic cage. This is consistent with data from the human CHD1 protein, where the H3-methylated peptide interacts with an acidic surface bridging chromodomains 1 and 2 ([@B44]). These data suggest a possible role of H3K4me2 in recruiting CHD8 to the chromatin. However, further *in vivo* experiments are required to confirm this hypothesis. Then we decided to investigate whether the level of CHD8 affects the degree of methylation of histone H3 in the *CCNE2* gene. ChIP experiments demonstrated that histone H3 is di- and tri-methylated in lysine 4 in the *CCNE2* promoter and 5′ transcribed region, irrespectively of the levels of CHD8 ([Figure 5](#F5){ref-type="fig"}C), indicating that CHD8 is not required for H3K4 methylation at the *CCNE2* gene. Figure 5.The tandem chromodomains of CHD8 bind to H3K4me2, *in vitro*. (**A**) Schematic of the CHD8 fragments used for binding studies. (**B**) Purified GST, GST-CD1, GST-CD2, GST-CD1+CD2, GST-CD1+mutCD2 and GST-mutCD1+CD2 proteins were incubated with different biotinylated histone H3 N-terminal peptides, such as unmodified (H3), Lys 4-di-methylated (H3K4me2), Lys 4-tri-methylated (H3K4me3) or Lys 9-di-methylated (H3K9me2). Bound fractions from the binding reactions were analyzed by western blotting using α-GST antibody. A representative experiment is shown. (**C**) Analysis of the levels of H3K4me2 and H3K4me3 in the 5′ region of the *CCNE2* gene by ChIP in C33KD2 cells treated or not with Dox during 72 h. Immunoprecipitated DNA from three independent experiments was quantified using qPCR. Numbers correspond to the center nucleotide of the real time PCR product relative to the transcription start site. Data are expressed as percentage of the input.

CHD8 associates with phosphorylated RNAPII
------------------------------------------

As a first step in the characterization of the mechanism by which CHD8 controls gene expression we investigated whether CHD8 interacts with RNAPII. When recruited to promoters, the CTD of the largest subunit of RNAPII is unphosphorylated (RNAPIIa). After promoter clearance and during early stages of elongation, firstly serine 5 (Ser5) and subsequently serine 2 (Ser2) are phosphorylated (Ser5-P and Ser2-P) (RNAPIIo) ([@B45]). The 8WG16 antibody recognizes mostly unmodified CTD repeats and some intermediate phosphorylated forms ([@B46]), while antibodies H14 and CTD4H8 recognize Ser5-P CTD and antibody H5 recognizes Ser2-P CTD repeats. In contrast, antibody N20 recognizes all RNAPII forms. Interestingly, CHD8 co-immunoprecipitated with hyperphosphorylated RNAPIIo complexes enriched for Ser5-P and Ser2-P ([Figure 6](#F6){ref-type="fig"}A). However, CHD8 did not co-immunoprecipitate with the transcription elongation factor SPT5 or with the HMG protein BRAF35 ([Figure 6](#F6){ref-type="fig"}A). Figure 6.CHD8 interacts with elongating RNAPII. (**A**) CHD8 associates with RNAPIIo *in vivo*. Immunoblot analysis of C33A total extract (input) and fractions immunoprecipitated with α-CHD8 or nonspecific antiserum (mock). Antibodies used for immunoblot are indicated on the left in each panel. (**B** and **C**) CHD8-depleted cells are hypersensitive to transcription elongation inhibitors. C33KD2 cells were grown with or without Dox and with or without flavopiridol (B) or DRB (C) at the indicated concentrations. Total cell numbers were determined after 5 days under the indicated conditions. Percentage of growth inhibition in the presence of either of flavopiridol (B) or DRB (C) is represented.

The fact that CHD8 associates with the elongating forms of RNAPII suggested that CHD8 might have a role in elongation. To support this hypothesis we asked whether CHD8-depleted cells were hypersensitive to inhibitors of transcription elongation. We reasoned that if elongation of some genes is altered in CHD8-depleted cells, a partial inhibition of elongation should enhance the effect of CHD8 depletion provoking a synthetic phenotype. Indeed, CHD8-depleted cells were hypersensitive to low concentrations of flavopiridol or 5,6-dichloro-1-β-[d]{.smallcaps}-ribofuranosylbenzimidazole (DRB), two drugs that impair elongation by inhibiting CDK9, a component of the P-TEFb complex ([@B47; @B48; @B49]) ([Figure 6](#F6){ref-type="fig"}B and C).

DISCUSSION
==========

Here we show that *CCNE2* is a direct target of CHD8. A number of results support this conclusion. First, CHD8-depleted cells present decreased levels of the *CCNE2* transcript and its protein. Second, CHD8 transactivates the *CCNE2* promoter in transient transfection experiments. And third, CHD8 binds directly to the *CCNE2* gene *in vivo*. We also provide several lines of evidence suggesting that CHD8 plays a positive role in the first steps of RNAPII elongation. First, CHD8 co-immunoprecipitates with RNAPII phosphorylated in serines 5 and 2 of its CTD, but not with non-phosphorylated RNAPII. Similarly to CHD8, other typical elongating factors such as Spt6, DSIF and the PAF complex associate with elongating RNAPII ([@B50; @B51; @B52]). Second, ChIP experiments demonstrate that CHD8 binds not only to the promoter but also to the promoter-proximal transcribed region of the *CCNE2* gene. In the same way, but unlike initiation factors, elongation factors such as DSIF, Spt6, TREX and PAF complexes associate with the coding region of active genes ([@B53; @B54; @B55]). Third, CHD8-depleted cells are hypersensitive to flavopiridol and DRB, drugs that provoke RNAPII arrest by inhibiting RNAPII CTD phosphorylation at serine 2 ([@B56],[@B57]). The fact that CHD8-depleted cells are hypersensitive to both inhibitors suggests that CHD8 acts in the same process that is being inhibited by the drugs. Although these experiments suggest a role for CHD8 during the first steps of elongation, we can not rule out an additional role for this factor in the formation of the pre-initiation complex.

As defined by Flaus *et al*., the ATPase CHD8 belongs to the CHD7 subfamily of the SNF2 family ([@B5]). In addition to CHD8, other three proteins belong to this subfamily in mammals: CHD6, CHD7 and CHD9. In contrast, only one protein called Kismet belongs to this subfamily in *Drosophila*. The *kismet* gene was originally identified as a suppressor of *Polycomb* mutations and, therefore, belongs to the trithorax group of genes ([@B58]). Kismet has been shown to play important roles in both segmentation and determination of body segment identity ([@B59]), and was found to co-localize with almost all RNAPII sites ([@B60]). *kis* mutants display a dramatic reduction in the levels of both CTD-Ser2 phosphorylated RNAPII and the elongation factors dSPT6 and dCHD1 on polytene chromosomes, suggesting that Kismet is required for transcription elongation ([@B60]). In contrast to *kis* mutations, CHD8 depletion does not generally reduce the levels of Ser2-phosphorylated RNAPII ([Figure 1](#F1){ref-type="fig"}). One possibility is that the function that Kismet performs in *Drosophila* is carried out in mammals by several members of the subfamily (CHD6 to CHD9). This would explain why the depletion of only one member of the subfamily does not have a general effect, but a gene-specific effect. This is consistent with our whole genome expression analysis, as only a small number of genes were found to be misregulated upon knocking down *CHD8*.

While preparing the revised version of this manuscript it has been reported that loss of Kismet function leads to a reduction in the level of the H3K4 methyl transferases TRX and ASH1 on polytene chromosomes ([@B61]). In agreement with the hypothesis that CHD8 and Kismet are functional orthologs, it has been shown that CHD8 co-purifies with components of the MLL1 (mixed-lineage leukemia) complex ([@B31],[@B62]), the mammalian TRX homolog. Moreover, and consistently with what we describe for CHD8, MLL1 has been found to interact with elongating RNAPII and bind to the promoters and 5′ transcribed regions of the genes. However, while MLL1 mostly associates with transcriptionally active genes, CHD8 binds to the *CCNE2* gene under conditions of both activation and repression. Furthermore, depletion of CHD8 does not affect the levels of H3K4me2 or H3K4me3, suggesting that CHD8 does not cooperate with the MLL1 complex for histone H3K4 methylation. Interestingly, Srinivasan *et al*. ([@B61]) have also shown that, despite the reduced recruitment of TRX and ASH1, the loss of Kismet has no effect on the level of H3K4 methylation on polytene chromosomes or over the *fkh* gene. The connection between H3K4 histone methyl transferases and Kismet/CHD8 proteins requires further investigation.

The way CHD8 is recruited to its target genes remains unknown. One possibility is that some specific histone modifications contribute to the recruitment of CHD8. Here we demonstrate that, in contrast to *Drosophila* Kismet ([@B61]), CHD8 directly binds *in vitro* to H3K4me2 through its tandem chromodomains. Consistently with our results, Yuan *et al*. recently used fractions enriched for CHD8 to demonstrate its direct or indirect association with di- and tri-methylated lysine 4 of histone H3 amino-terminal peptides ([@B63]). We also found that CHD8 is constitutively bound to the *CCNE2* gene, even during G1, when the gene is not active. This is also consistent with the fact that CHD8 interacts with histone H3K4me2 *in vitro*, since H3K4me3 correlates with actively transcribed genes while H3K4me2 can be present on poised, inactive genes ([@B64],[@B65]). Interestingly we also found significant levels of RNAPII associated to the *CCNE2* gene under conditions of repression. Promoter-proximal pausing ([@B1]) is a widespread phenomenon that takes place in many genes, where RNAPII pauses in the 5′ region of transcription units and only progresses into productive elongation upon stimulation by appropriate signals. Paused RNAPII is phosphorylated at serine 5 of its CTD. The association of CHD8 with the repressed *CCNE2* gene and the fact that it interacts with Ser5-P-RNAPII suggest that CHD8 might be recruited to genes having paused RNAPII.

CHD8 may also be recruited to its targets by interaction with specific transcription factors. In fact, it has been shown that CHD8 associates with human staf/ZNF143, a zinc finger protein that controls the expression of the U6 gene ([@B63]), and with β-catenin ([@B31]). In this respect we found that, although CHD8 is required for normal expression of *CCNE2* and *TYMS*, two G1/S-specific genes which are targets of the E2F1 transcription factor ([@B41]), the expression of other typical E2F1-dependent genes such as *CCNE1*, *CCNA2*, *TK1*, *PCNA* or *E2F1* itself did not change significantly under conditions of CHD8 depletion. Nonetheless and interestingly, we have verified the presence of CHD8 in the 5′ region of *CCNE1* and *TK1* by ChIP experiments (data not shown). Furthermore, in transient transfection experiments CHD8 was also able to activate the expression of a minimal promoter containing an E2F1 synthetic binding site (data not shown). One possibility is that E2F1 could recruit CHD8 to all E2F1-dependent genes but that only those genes with a specific chromatin structure at the 5′ region require CHD8 for normal elongation. Therefore, we suggest that the specificity of CHD8 for a subset of genes may involve its interaction with specific transcription factors, specific histone modifications and the phosphorylation status of RNAPII.
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